Literature DB >> 6782151

Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.

B Busnardo, M E Girelli, F Bui, G P Zanatta, M Cimitan.   

Abstract

Measurements of serum triiodothyronine (T3) concentrations were made in 46 patients who had thyroid ablation for thyroid cancer and who were receiving T3 three times a day as suppressive treatment. In all patients thyrotropin (TSH) suppression was confirmed by the inhibition of TSH response to thyrotropin releasing hormone (TRH). The suppressive dose of T3 varied from 40 to 100 micrograms/day (mean +/- SD 72.39 +/- 13.07 micrograms/day). Related to body weight the dose varied from 0.95 to 1.35 micrograms/kg/day (mean +/- SD 1.13 +/- 0.13 micrograms/kg/day). In ten hospitalized patients serum T3 levels were measured at hourly intervals from 08:00 to 23:00. Before the first dose of T3, serum T3 levels were 153 +/- 43 mg/100 ml; after T3 the levels increased promptly reaching after 4 h a peak of 264 +/- 90 ng/100 ml. Afterwards T3 levels showed a similar peak after each dose: 262 +/- 77 and 266 +/- 78 ng/100 ml, slightly decreasing in the intervals between the doses: 227 +/- 63 and 255 +/- 69 ng/100 ml. After the last peak T3 levels showed a slow decline during the night. TSH response to TRH was completely inhibited both at 08:00 and at 16:00. In 36 outpatients T3 levels were measured twice a day and T3 levels were found similar to the ones of the first group. In these patients also TSH response to TRH evaluated at 08:00 was completely inhibited. No important side effect was noted in both groups of patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6782151     DOI: 10.1007/BF03349370

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Relationships between metastases of differentiated thyroid carcinoma and serum thyrotropin (TSH) levels.

Authors:  B Busnardo; M E Girelli; M Cimitan; D Casara; F Bui; C Lassi; G Argenti
Journal:  J Clin Endocrinol Metab       Date:  1977-06       Impact factor: 5.958

2.  Replacement dosage of L-thyroxine in hypothyroidism. A re-evaluation.

Authors:  J M Stock; M I Surks; J H Oppenheimer
Journal:  N Engl J Med       Date:  1974-03-07       Impact factor: 91.245

3.  Circadian variation of the serum thyrotropin level in normal subjects.

Authors:  J Weeke
Journal:  Scand J Clin Lab Invest       Date:  1973-05       Impact factor: 1.713

4.  Thyroxine: just a prohormone or a hormone too?

Authors:  I J Chopra; D H Solomon; G N Chua Teco
Journal:  J Clin Endocrinol Metab       Date:  1973-06       Impact factor: 5.958

5.  Circadian variations of serum thyrotropin levels in man.

Authors:  L Vanhaelst; E Van Cauter; J P Degaute; J Golstein
Journal:  J Clin Endocrinol Metab       Date:  1972-09       Impact factor: 5.958

6.  Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma.

Authors:  J M Hershman; C L Edwards
Journal:  J Clin Endocrinol Metab       Date:  1972-05       Impact factor: 5.958

7.  Methods of follow-up for treated thyroid carcinomas.

Authors:  R Mornex; B Hugues; L Perrot
Journal:  Ann Radiol (Paris)       Date:  1977 Nov-Dec

8.  The role of radiotherapy and radioactive iodine in the treatment of thyroid cancer without metastases.

Authors:  M Tubiana; P Charbord; W Cukersztein; D Sarrazin; F Fontaine; C Parmentier
Journal:  Ann Radiol (Paris)       Date:  1977 Nov-Dec

9.  TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.

Authors:  B Busnardo; R Vagelista; M E Girelli; F Bui; C Lazzi
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

10.  Why does anyone still use desiccated thyroid USP?

Authors:  I M Jackson; W E Cobb
Journal:  Am J Med       Date:  1978-02       Impact factor: 4.965

View more
  2 in total

1.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

2.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.